Fairvalue-Calculator Fairvalue-Calculator
EN DE

TiumBio Co (321550) Fair Value & Analysis

Healthcare · KR · Market cap 134B KRW

Price4,270 KRW
Fair Value2,705 KRW
Upside-36.6%
Quality91/100
Evidence: Low Range 2,029 KRW – 3,382 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

TiumBio Co (321550) currently trades at 4,270 KRW, while our model-based Fair Value estimate is 2,705 KRW — implying the stock looks roughly 36.6% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is TiumBio Co (321550) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2,705 KRW versus a price of 4,270 KRW — about −37% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 321550?
Our 21-model fair value for TiumBio Co is 2,705 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 4,270 KRW.
What is the quality score of 321550?
TiumBio Co has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.